1. Generics Bulletin
  2. >>Products

Medicure And Reliance Shake Hands On Cardiovascular Biosimilar

Indian Firm Has Xolair Rival

 
• By Dean Rudge

Medicure will take responsibility for gaining approval for an unnamed cardiovascular biosimilar that it has just agreed to license from India’s Reliance Life Sciences in the US, Canada and the EU.

Lungs
Medicure has identified cardiovascular as its primary focus • Source: Shutterstock

Medicure International has struck a license, manufacture and supply agreement with India’s Reliance Life Sciences for an undisclosed biosimilar product to treat cardiovascular diseases, furthering the firm’s ambitions of being a “significant cardiovascular company focused on the US market.”

Under the terms of the agreement, the Medicure subsidiary is responsible for the regulatory approval process for the product and will pick up the exclusive right from Reliance Life Sciences

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products

Amneal Proud To Be ‘Made In America’ And Ready To Scale Up Its US Manufacturing

 
• By Urtė Fultinavičiūtė

Amneal has set itself apart from competitors who are scrambling to find alternatives if proposed US pharmaceutical tariffs come into place. For the New Jersey-based firm, this is an opportunity to embrace its American identity and open a new chapter of growth.

‘I’ll Be Happy When We Have 40-Plus Assets’ – Sandoz Builds Up Biosimilars

 
• By Dave Wallace

With biosimilars playing an increasingly important role in Sandoz’s business, the firm’s first-quarter results call saw management lay out the latest key developments. Meanwhile, the company also addressed the issue of US tariffs, voicing optimism over both future developments as well as its ability to weather current measures.

Tetris Deal Falls Into Place For UK’s Aspire

 
• By Dave Wallace

Niche generics company Aspire Pharma has struck a deal to acquire a portfolio of products from fellow UK firm Tetris Pharma as it is wound up, paying Tetris parent Arecor £0.5m for UK distribution rights and inventory.